Decades of experience, dozens of perspectives
We value diversity of background and mindset just as highly as experience and technical knowledge.
Our executive team, board, and scientific personnel are a diverse mix of ages, genders, backgrounds, and ethnicities, with more than 80% holding PhDs with specialties from cell biology to computer science.
It’s this diversity and originality, powered by a shared passion for delivering innovative healthcare solutions for all, that truly makes the SOPHiA GENETICS team unique.
Our Executive Team
Co-Founder and CEO
Dr. Jurgi Camblong, Ph.D., M.B.A., is a visionary entrepreneur who is pioneering the data-driven medicine movement around the world.
He is a molecular biologist (published in Cell, Science and Nature), has a Ph.D. in life sciences from the University of Geneva and an Executive M.B.A. in management of technology from EPFL/HEC Lausanne.
In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz and has been a member of the board of directors since March 2011. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Jurgi was a member of the Advisory Council on Digital Transformation to the Swiss Government, is a board member of the Swiss Biotech Association and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.
EVP – Chief Medical Officer & Chief Product Officer
Dr. Philippe Menu, M.D., Ph.D., M.B.A., brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology, and business management consulting. He joined SOPHiA GENETICS in February 2020 as our Chief Medical Officer from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players, and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases.
Prior to that Philippe was a post-doctoral fellow at the University of Lausanne. As of March 15, 2023, Philippe has been appointed as our Chief Product Officer & Chief Medical Officer.
Philippe holds an M.D. and a Ph.D. from the University of Lausanne, and an M.B.A. in life sciences from the Open University Business School.
SVP – Chief People Officer
Manuela Da Silva Valente, B.A., is a seasoned human resources executive with more than 20 years of experience working in international companies. Manuela joined SOPHiA GENETICS in January 2019 as our Chief People Officer from IQVIA (formerly Quintiles and IMS Health, Inc.), a human data science company, where she had a number of senior human resources roles, including from 2016 to 2018 the position of Global Senior Director of Human Resources .
Prior to this, she worked for several years at Outcome Sciences, where she successfully established European operations and led the organization through an acquisition by Quintiles.
Manuela obtained a Bachelor’s degree in business administration from the Business Management School of Zurich and a management & human resources diploma from CEFCO Lausanne.
Used to working in fast-pacing companies, Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes by focusing on talent development and employee engagement.
Abhimanyu (Abhi) Verma
SVP – Chief Technology Officer
Abhimanyu (Abhi) Verma, M.Sc., M.B.A., is a healthcare technology leader experienced in developing capabilities and leading multifunctional organizations to create and accelerate solutions that impact patients and joined SOPHiA GENETICS in February 2022. He has more than 17 years of life sciences industry experience centered on harnessing the intersection of people, science, technology, data & AI serving multiple therapeutic areas and functions across the pharma value chain.
His leadership experience spans creating technology & information strategies; operating models; building teams and products; running operational platforms; and driving organizational and cultural transformation, with a relentless focus on outcomes and execution. Previously at Novartis, Abhi has proven to be a thought leader and execution champion at innovating and scaling data science and technology products, methodologies and approaches.
Passionate about cycling, comics, science fiction, and history, Abhi holds an M.B.A. from the Indian School of Business, a Master of Science in pharmaceutical medicine and is an engineer. He is also co-founder of the nonprofit Health Hacking Lab.
EVP – Chief Scientific Officer
Zhenyu Xu, Ph. D., is a genome scientist with a background in molecular and computational biology. Zhenyu is among the most experienced bioinformaticians in clinical NGS data analysis worldwide. He joined SOPHiA GENETICS in January 2012 and is the leader of the technology team that developed the SOPHiA DDM™ platform – the universal technology for data-driven medicine.
Zhenyu has served as our Chief Scientific Officer since January 2021 and was previously our Chief Technology Officer since May 2014. Prior to that, Zhenyu was a post-doctoral fellow at the European Molecular Biology Laboratory.
Zhenyu holds an M.Sc. in molecular and computational biology from Cambridge University and obtained his Ph.D. at the European Molecular Biology Laboratory, where he focused on the transcriptome landscape of yeast. His Ph.D. work systematically characterized the non-coding transcripts in yeast that lead to the unveiling that, in a majority of cases, transcriptions are bidirectional.
EVP – Chief Financial Officer & Chief Operating Officer
Ross Muken, B.Sc., joined SOPHiA GENETICS in February 2021 as Chief Financial Officer. As of March 15, 2023, Ross has been appointed as our Chief Financial Officer & Chief Operating Officer. Previously, he was CFO & COO of Click Therapeutics.
Before joining Click, he was partner, Senior Managing Director and head of the healthcare services & technology equity research team at Evercore/ISI Group, where he covered more than 50 companies across the healthcare technology & distribution, life science tools & diagnostics, managed care & facilities and medical supplies & devices subsectors.
Prior to joining Evercore ISI, Ross served as Senior Managing Director at Deutsche Bank Securities and spent time in the equity research division of Thomas Weisel Partners. He began his career as an M&A investment banker at Bank of America Securities after earning his B.Sc. in business administration, magna cum laude, at Boston University.
Daan Van Well
SVP – Chief Legal Officer and General Counsel
Daan van Well, LL.M., M.B.A., has more than 20 years of experience as a lawyer in top-tier private practice, in-house, and consulting roles. He has extensive experience in legal, governance, and compliance matters. From 2018 to 2019, Daan served as the founder and managing partner of consulting firm SpringWorks Sàrl.
Prior to joining SOPHiA GENETICS in June 2019, since 2011 he was the head of legal at PwC in Geneva, Switzerland where he supported a variety of clients with company mergers and acquisitions, business development, governance, and compliance matters.
Before that, after having held several in-house roles, Daan served as corporate secretary for international food retailer Ahold (currently Ahold Delhaize), listed at the New York Stock Exchange and at AEX Euronext Amsterdam, where he oversaw all corporate activities, corporate finance, and investor relations work.
Daan holds an LL.M. in Dutch civil law from Utrecht University and an Executive M.B.A. in management and corporate finance from HEC Lausanne.
SVP – Chief Regulatory Officer
Melissa Finocchio, M.Sc., is an experienced regulatory and quality professional with more than 20 years of experience in in vitro diagnostics. Before joining SOPHiA GENETICS in May 2021, she worked for bioMérieux where she held various positions in product development, project management, complaint handling, labeling, and quality.
Melissa has lived and worked in multiple countries, which has allowed her to extensively experience first-hand the challenges of cross-cultural communication and international management on a global scale. Melissa is passionate about the role of quality in facilitating efficient operations.
She received her undergraduate degree in Engineering Management from the University of Missouri-Rolla (now Missouri University of Science & Technology) and her Master’s degree in quality management from Webster University. She is also an American Society of Quality certified Reliability Engineer and Quality Engineer.
SVP – Chief BioPharma Officer
Peter Casasanto, M.B.A., is an executive in the life sciences industry with experience and expertise spanning both corporate and business development and sales strategy, supporting biomarker development and precision medicine. He joined SOPHiA GENETICS in January 2022. He started in the industry 15 years ago as a scientist at Merck in their Vaccines & Biologics group.
Peter’s professional experience includes business development in his early days, moving to sales, client management, and growth strategy for BioPharma portfolios. He has also led teams through the processes of an M&A.
Most recently, Peter has worked at CellCarta leading the commercial strategies for new corporate initiatives spanning companion diagnostics/single-site IVD, new product launch and Go-to-Market for an in-house developed SaaS (software) analytics platform, as well as AI-driven mutiomic-based insights and predictions.
Peter holds an M.B.A in pharmaceutical management from Drexel’s LeBow College of Business, a Master’s degree in biomedical chemistry from Thomas Jefferson Medical School and B.Sc. in immunology & genomics from the University of Maryland at College Park.
SVP – Chief Revenue Officer
Ken Freedman, M.A., joined SOPHiA GENETICS in January 2022. He is an accomplished executive with more than 25 years of experience in sales, marketing, and executive management experience.
His background includes sales, management, and holding executive roles for some of the most innovative providers of technology to the worldwide media space, including Agfa, FileFlow, Prepress Solutions, and MediaSpan.
Ken was part of the executive team involved in selling MediaSpan to Vista Equity Partners during the early days of Newscycle. An expert at finding and growing new revenue streams, building processes, and helping customers find success, he ultimately went on to lead all sales activities from Canada to Latin America.
Ken graduated from UMass Amherst with a degree in mass communications. He lives in Falmouth, MA with his wife and has two daughters.
VP – Business Development & Marketing
Kevin Puylaert is the VP of Business Development & Marketing at SOPHiA GENETICS. He joined the company in March 2016. With a passion for innovation and a drive to bring solutions to healthcare professionals around the world, Kevin leads the company’s efforts to accelerate the adoption of the SOPHiA DDM™ Platform through strategic partnerships and marketing.
With his industry expertise and entrepreneurial spirit, Kevin has been instrumental in the growth of SOPHiA GENETICS, driving the company’s global expansion through his expertise in developing and executing successful business strategies. Under his leadership, Kevin launched the Boston office and successfully introduced SOPHiA GENETICS to the US market.
With a background in science and business, Kevin holds a Master’s degree in science from the Louvain School of Management, Belgium, and a Bachelor’s degree in business engineering from the University of Leuven, Belgium.
Board of Directors
Co-Founder and CEO
Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the data-driven medicine movement around the world.
He is a molecular biologist (published in Cell, Science and Nature), has a PhD in life sciences from the University of Geneva and an EMBA in management of technology from EPFL/HEC Lausanne.
In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Jurgi has been a member of the Advisory Council on Digital Transformation to the Swiss government and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.
Chairman of the Board
Troy Cox, M.B.A, is a pioneer in the precision medicine revolution. Former CEO of Foundation Medicine (acquired by Roche in 2018), Troy is making a difference in patient’s lives by serving on corporate boards of innovative companies in the BioPharma, diagnostics and tech industries.
He is also committing his support to patient-focused non-profit organizations. In June 2019, Troy joined SOPHiA GENETICS as the chairman of the board of directors to help the organization further advance data-driven medicine. From 2017 to 2019, Troy served as the Chief Executive Officer of Foundation Medicine, Inc.
Prior to Foundation Medicine, Troy served as the Senior Vice President of U.S. Commercial of Genentech, Inc. where he led US bio-oncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Prior to that, Troy held various executive and senior positions at UCB S.A., Sanofi-Aventis U.S. LLC and Schering-Plough Corporation. In addition to our board of directors, Troy serves on the board of directors of Zymeworks, Inc., LetsGetChecked, Somalogic, Inc., BioSplice Therapeutics, Inc. and previously served on the board of directors of Foundation Medicine, Inc.
Troy’s expertise spans across strategy, general management, commercial and R&D. His pharmaceutical career began as a sales representative after earning his MBA at the University of Missouri. He has also received a B.B.A. in finance from the University of Kentucky.
Kathy Hibbs, J.D., is an accomplished healthcare technology executive and active board member with more than two decades of expertise in healthcare and genomics. Since 2022, she has served as the Chief Administrative Officer of 23andMe and prior to that role as the Chief Legal and Regulatory Officer of 23andMe from 2014 to 2022, where she leads its complex legal operations and regulatory affairs. She is globally recognized for her effectiveness, having successfully pioneered the first FDA clearance for over-the-counter genetic testing.
Regularly recognized as one of the Bay Area’s most influential women by both the San Francisco Business Times and Silicon Valley Business Journal, Kathy is ranked by Chambers as among the most influential general counsel in the US. She sits on the board of Cadex Genomics, Inc. and previously served on the board of directors of Decipher Biosciences, Inc. During her 15 years as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX), Monogram Biosciences, Inc. (NASDAQ: MGRM) and in the leadership team of Varian Medical Systems, Inc. (NASDAQ: VAR) involved in legal, business development and compliance matters, Kathy developed her passion for personalized medicine and the power of innovation to improve the lives of patients. Kathy graduated summa cum laude from the University of California, Riverside, where she received her J.D. from Hastings College of Law.
Didier Hirsch, M.Sc., M.S., has served as a member of our board of directors since June 2020. Didier Hirsch was Senior Vice President and Chief Financial Officer of Agilent Technologies, Inc., a global leader in life sciences, diagnostics and applied chemical markets, from 2010 to 2018. He joined Agilent in 1999 at its inception, holding multiple leadership roles in finance.
Prior to joining Agilent Technologies, Inc., Didier was with Hewlett-Packard Company, serving in leadership roles in finance and administration in EMEA and Asia Pacific beginning in 1989. Previously, he held finance positions at Valeo Inc., Gemplus S.C.A., SGS-Thomson Microelectronics, I.B.H. Holding S.A., Bendix Corporation and Ford Motor Company.
Didier serves on the board of directors of Knowles Corporation and previously served on the board of directors of Logitech International S.A. and International Rectifier Corporation. He is the chair of the audit committee and a member of its nominating committee.
Didier holds an M.S. in computer science from Toulouse University in France and an M.Sc. in industrial administration from Purdue University in the US.
Vincent Ossipow, Ph.D., CFA has served as a member of our board of directors since June 2014. He has been a partner at Omega Funds, where he served as Chief Scientific Officer of Omega Alpha SPAC, and brings 22 years of healthcare investment experience in public and private companies.
Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a partner for private equity. Prior to that, he was with Pictet Bank where he co-managed the Pictet Biotech Fund.
Vincent has extensive board member experience. In addition to our board of directors, Vincent serves on the board of directors of Immunic, Inc. (NASDAQ: IMUX), BioInvent International AB (STO: BINV), FoRx SA, SwissThera SA, and eTheRNA immunotherapies NV, and previously served on the board of directors of Andrew Alliance S.A., Lifespan, Inc., Raindance Technologies, CNx SA and Kuros Biosciences AG. He served on the board of directors of a dozen public and private companies over the past decade..
As a research fellow at the University of Geneva from 2000 to 2006, where he obtained a Ph.D. in molecular biology, he worked on the molecular basis of brain function.
Vincent trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute in Bethesda, Maryland. He completed a certificate in international finance and global markets at the Georgetown University School of Business in Washington, D.C.
Milton G. Silva-Craig, J.D., M.B.A., who has served as a member of our board of directors since 2019, is a successful leader who has demonstrated expertise in building inclusive, high-performance teams that have grown and scaled businesses in various fields of provider healthcare IT, including medical imaging, revenue cycle management and clinical data management.
He has been the Chief Executive Officer of Q-Centrix, LLC since early 2014, leading theompanyy through a successful sale from private equity firm Sterling Partners to TPG Growth in late 2018.
Prior to Q-Centrix, he served as president of TransUnion LLC’s healthcare business unit, he developed and executed a strategic business plan focused on repositioning and growing TransUnion in the healthcare marketplace.
Prior to TransUnion LLC, Milton served as an executive at Technology Solutions Company and as President and Chief Operating Officer at Emageon, Inc., leading the company’s strategic direction and operations. He grew revenues from several hundred thousand dollars to more than $100 million and eventually led Emageon through its initial public offering on NASDAQ in 2005 (NASDAQ:EMAG). He also held executive positions at General Electric Healthcare.
In addition to our board of directors, Milton serves on the board of directors for Q-Centrix, LLC and previously served on the board of directors of HealthMyne, Inc.
Silva-Craig earned a J.D. from the University of Wisconsin School of Law in Madison and obtained his M.B.A. and B.A. from the University of Wisconsin – Madison.
Tomer Berkovitz, Ph.D., has served as a member of our board of directors since March 2021. Since 2018 he has served as a General Partner at aMoon, where he co-leads aMoon’s Growth Fund. As a former investment banker and senior executive in public companies, Tomer witnessed how the sectors of healthcare and technology were converging into a new industry that had the potential to make a global impact.
Tomer places his relationship with our portfolio companies’ CEOs and founders as his top priority, partnering with entrepreneurs to enhance the value and growth of their company. Since joining aMoon in early 2018, Tomer has led the $55M Series D round of Seer (NASDAQ: SEER) and supported the company through additional private financing, spin-off and successful IPO. Tomer also led the $55M Series B of PrognomIQ and the $30M Series C round of Zebra Medical Vision, serving as a board member in both companies. Tomer also led SOPHiA GENETICS’ $110M Series F round and serves as the Chairman of its Strategy Committee.
Tomer started his Wall Street career as an investment banker at J.P. Morgan in New York, where he was promoted to a position as executive director in record time. In this role, he led numerous capital market and mergers and acquisitions transactions. After J.P. Morgan, Tomer was appointed CFO & COO of Alcobra Ltd., a NASDAQ–listed biopharmaceutical company, where he served as Chief Operating Officer and Chief Financial Officer and led public equity offerings and its merger with Arcturus Therapeutics. Tomer earned his Ph.D. in finance (with distinction) from Columbia Business School.
Jean-Michel Cosséry, Ph.D., Pharm.D., M.B.A is a senior healthcare executive with global leadership experience in research, marketing, and commercial roles in med-tech and pharmaceuticals and has served as a member of our board of directors since June 2022 From 2012 to 2018, Jean-Michel served in various senior leadership positions at Eli Lilly and Company, including as Vice President, North America Oncology, as well as Vice President and Managing Director of Lilly UK and Northern Europe. Prior to that, he served as Vice President and Chief Marketing Officer of GE Healthcare as well as in senior positions at Novartis International AG and Serono (now Merck (Schweiz) AG). Jean-Michel serves on the board of directors of Malin Corporation plc, Exact Therapeutics AS, and Eracal Therapeutics Ltd., and serves as the non-executive chairman of Scancell Holdings PLC. Previously, he served on the board of directors of ABPI (UK) LIMITED, Immunocore Holdings Limited, until its IPO, Kymab Ltd, until its sale to Sanofi, and Diurnal PLC, and as chairman of the board of directors of the American Pharmaceutical Group in the UK.
Jean-Michel holds an M.B.A. from the Rotterdam School of Management and a Ph.D. with honors in nuclear chemistry and neurobiology from Paris Sud University. Additionally, he holds a Pharm.D. with honors in pharmacology from Paris.